Chapter 1: Introduction .. 2
Study Goals and Objectives 2
Reasons for Doing this Study 2
Scope of Report 3
Information Sources .. 3
Methodology . 3
Geographic Breakdown 3
Analyst's Credentials .. 11
Related BCC Research Reports.. 11
Chapter 2: Summary and Highlights 13
Chapter 3: Disease Overview 18
Malaria .. 18
Incidence and Geographical Distribution .. 18
Etiology and Symptoms 20
Socioeconomic Burden . 20
Current Method of Treatment . 21
Leishmaniasis . 23
Incidence and Geographical Distribution .. 23
Etiology and Symptoms 26
Socioeconomic Burden . 27
Current Method of Treatment . 28
Schistosomiasis . 29
Incidence and Geographical Distribution .. 29
Etiology and Symptoms 30
Socioeconomic Burden . 31
Current Method of Treatment . 32
Lymphatic Filariasis . 32
Incidence and Geographical Distribution .. 32
Etiology and Symptoms 33
Socioeconomic Burden . 34
Current Method of Treatment . 34
Chagas Disease .. 35
Incidence and Geographical Distribution .. 35
Etiology and Symptoms 35
Socioeconomic Burden . 36
Current Method of Treatment . 38
African Trypanosomiasis .. 38
Incidence and Geographical Distribution .. 38
Etiology and Symptoms 40
Socioeconomic Burden . 40
Current Method of Treatment . 42
Dengue .. 43
Incidence and Geographical Distribution .. 43
Etiology and Symptoms 45
Socioeconomic Burden . 45
Current Method of Treatment . 47
Ebola .. 47
Incidence and Geographical Distribution .. 47
Etiology and Symptoms 48
Socioeconomic Burden . 49
Current Method of Treatment . 49
Zika .. 50
Incidence and Geographical Distribution .. 50
Etiology and Symptoms 50
Socioeconomic Burden . 51
Current Method of Treatment . 51
Chapter 4: Market Overview .. 53
Total Addressable Market .. 53
Malaria .. 56
Malaria - Market Share by Geography 56
Leishmaniasis . 58
Leishmaniasis - Market Share by Geography .. 58
Schistosomiasis . 59
Schistosomiasis - Market Share by Geography .. 60
Lymphatic Filariasis . 61
Lymphatic Filariasis - Market Share by Geography .. 61
Chagas Disease .. 63
Chagas Disease - Market Share by Geography 63
African Trypanosomiasis .. 64
Dengue .. 64
Dengue - Market Share by Geography 65
Ebola .. 67
Zika .. 67
Zika - Market Share by Geography 68
Donations by Pharmaceutical Companies: Access to Medicines . 70
Chapter 5: Market Influencing Factors . 72
Market Drivers .. 72
Malaria . 74
Leishmaniasis .. 75
Lymphatic Filariasis .. 75
Chagas Disease .. 75
African Trypanosomiasis . 75
Dengue 76
Ebola 76
Zika . 76
Market Deterrents .. 77
Malaria . 78
Leishmaniasis .. 78
Schistosomiasis . 79
Lymphatic Filariasis . 79
Chagas Disease 79
African Trypanosomiasis .. 79
Dengue . 80
Ebola . 80
Zika . 80
Unmet Needs . 80
Malaria . 81
Leishmaniasis .. 82
Schistosomiasis .. 82
Lymphatic Filariasis .. 83
Chagas Disease 83
African Trypanosomiasis .. 83
Dengue . 84
Ebola . 84
Zika . 84
Chapter 6: Research and Development 86
Malaria .. 86
Clinical Trials in Malaria 90
Leishmaniasis . 91
Clinical Trials in Leishmaniasis .. 93
Schistosomiasis . 94
Clinical Trials in Schistosomiasis .. 95
Lymphatic Filariasis . 96
Clinical Trials in Lymphatic Filariasis . 96
Chagas Disease .. 97
Clinical Trials in Chagas Disease .. 98
African Trypanosomiasis 100
Clinical Trials in African Trypanosomiasis 101
Dengue 101
Clinical Trials in Dengue . 103
Ebola 104
Clinical Trials in Ebola .. 106
Zika 107
Clinical Trials in Zika . 109
Chapter 7: Patent Review . 112
Malaria 112
Patent Review by Assignee .. 112
Patent Review by Year . 114
Patent Review by Country . 115
Patent Review by Type 117
Leishmaniasis .. 118
Patent Review by Assignee .. 118
Patent Review by Year . 119
Patent Review by Country . 120
Patent Review by Type 122
Schistosomiasis .. 123
Patent Review by Assignee .. 123
Patent Review by Year . 124
Patent Review by Country . 124
Patent Review by Type 125
Lymphatic Filariasis .. 126
Patent Review by Assignee .. 126
Patent Review by Year . 127
Patent Review by Country . 127
Patent Review by Type 128
Chagas Disease 129
Patent Review by Assignee .. 129
Patent Review by Year . 130
Patent Review by Country . 131
Patent Review by Type 132
African Trypanosomiasis 133
Patent Review by Assignee .. 133
Patent Review by Year . 134
Patent Review by Country . 134
Patent Review by Type 135
Dengue 136
Patent Review by Assignee .. 136
Patent Review by Year . 138
Patent Review by Country . 139
Patent Review by Type 141
Ebola 142
Patent Review by Assignee .. 142
Patent Review by Year . 144
Patent Review by Country . 145
Patent Review by Type 147
Zika 148
Patent Review by Assignee .. 148
Patent Review by Year . 148
Patent Review by Country . 149
Patent Review by Type 150
Chapter 8: Company Profiles .. 153
Appendix: Abbreviations 174
About BCC Research .. 178
About BCC Research. 179
BCC Library Access 179
BCC Custom Research . 179

List of Tables
Summary Table: Global Market for Neglected Tropical Diseases, by Indication, Through 2021 ($ Millions)
..14
Table 1 Key Trends in Neglected Tropical Diseases 16
Table 2 Estimated Malaria Incidence (per 1,000 at Risk), 2000-2015 ..18
Table 3 Suspected Malaria Cases, 2010-2015 (Millions)19
Table 4 Confirmed Malaria Cases, 2010-2015 (Millions) ..19
Table 5 Estimated Spending on Malaria Treatment in Sub-Saharan Africa, 2010-2014 ($ Millions)..20
Table 6 WHO Guidelines for Treatment of Malaria ..22
Table 7 Number of Cases of CL in Select High Burden Countries, 2010-2014 .23
Table 8 Number of Cases of VL in Select High Burden Countries, 2010-2014.24
Table 9 Incidence of CL and VL in High Burden Countries, 2014 (Cases per 10,000 Inhabitants in
Endemic Areas) .25
Table 10 Global Disease Burden of Leishmaniasis, 2015 27
Table 11 WHO Guidelines for Treatment of Leishmaniasis ..28
Table 12 Number of People Treated Globally, 2010-2014 (Millions) .30
Table 13 Global Disease Burden of Schistosomiasis, 2015 (Years) 31
Table 14 Global Disease Burden of Lymphatic Filariasis, 2015 (Years)34
Table 15 Prevalence and Incidence (Number) of Chagas Disease, 2015 35
Table 16 Global Disease Burden of Chagas Disease, 2015 (Years) 36
Table 17 Prevalence and Incidence (Number) of Chagas Disease, 2015 39
Table 18 Global Disease Burden of African Trypanosomiasis, 2015.41
Table 19 Prevalence and Incidence (Number) of Dengue Cases, 2015 ..43
Table 20 Reported Cases and Deaths in Ebola Outbreaks, 2007-201647
Table 21 Zika Burden, 2015-2016 ..51
Table 22 Global Addressable Market for Neglected Tropical Diseases, by Indication, Through 2021 ($
Millions) 54
Table 23 Global Addressable Market for Malaria, by Region, Through 2021 ($ Millions)57
Table 24 Global Addressable Market for Leishmaniasis, by Region, Through 2021 ($ Millions) ..58
Table 25 Global Addressable Market for Schistosomiasis, by Region, Through 2021 ($ Millions) ..60
Table 26 Global Addressable Market for Lymphatic Filariasis, by Region, Through 2021 ($ Millions)..62
Table 27 Global Addressable Market for Chagas Disease, by Geography, Through 2021 ($ Millions)..63
Table 28 Global Addressable Market for Dengue, by Region, Through 2021 ($ Millions)65
Table 29 Global Addressable Market for Zika, by Region, Through 2021 ($ Millions)68
Table 30 Drug Donation Commitments, by WHO..70
Table 31 Malaria Development Pipeline and Recent Launches..86
Table 32 Leishmaniasis Development Pipeline and Recent Launches.92
Table 33 Schistosomiasis Development Pipeline and Recent Launches.94
Table 34 Lymphatic Filariasis Development Pipeline and Recent Launches.96
Table 35 Chagas Disease Development Pipeline and Recent Launches .97
Table 36 African Trypanosomiasis Development Pipeline and Recent Launches101
Table 37 Dengue Development Pipeline and Recent Launches101
Table 38 Ebola Development Pipeline and Recent Launches 105
Table 39 Zika Development Pipeline and Recent Launches108
Table 40 Number of Patent Applications, Malaria, by Assignee113
Table 41 Number of Patent Applications, Malaria, by Year, 2010-2015 114
Table 42 Number of Patent Applications, Malaria, by Country 115
Table 43 Number of Patent Applications, Malaria, by Type ..117
Table 44 Number of Patent Applications, Leishmaniasis, by Assignee . 118
Table 45 Number of Patent Applications, Leishmaniasis, by Year, 2010-2015. 119
Table 46 Number of Patent Applications, Leishmaniasis, by Country .. 120
Table 47 Number of Patent Applications, Leishmaniasis, by Type .. 122
Table 48 Number of Patent Applications, Schistosomiasis, by Assignee . 123
Table 49 Number of Patent Applications, Schistosomiasis, by Year, 2010-2015 . 124
Table 50 Number of Patent Applications, Schistosomiasis, by Country .. 125
Table 51 Number of Patent Applications, Schistosomiasis, by Type . 126
Table 52 Number of Patent Applications, Lymphatic Filariasis, by Assignee . 126
Table 53 Number of Patent Applications, Lymphatic Filariasis, by Year, 2010-2015 127
Table 54 Number of Patent Applications, Lymphatic Filariasis, by Country 128
Table 55 Number of Patent Applications, Lymphatic Filariasis, by Type . 129
Table 56 Number of Patent Applications, Chagas Disease, by Assignee . 129
Table 57 Number of Patent Applications, Chagas Disease, by Year, 2010-2015 .. 130
Table 58 Number of Patent Applications, Chagas Disease, by Country 131
Table 59 Number of Patent Applications, Chagas Disease, by Type 133
Table 60 Number of Patent Applications, African Trypanosomiasis, by Assignee .. 133
Table 61 Number of Patent Applications, African Trypanosomiasis, by Year, 2010-2015 . 134
Table 62 Number of Patent Applications, African Trypanosomiasis, by Country . 135
Table 63 Number of Patent Applications, African Trypanosomiasis, by Type .. 136
Table 64 Number of Patent Applications, Dengue, by Assignee .. 136
Table 65 Number of Patent Applications, Dengue, by Year, 2010-2015 . 138
Table 66 Number of Patent Applications, Dengue, by Country 139
Table 67 Number of Patent Applications, Dengue, by Type .. 141
Table 68 Number of Patent Applications, Ebola, by Assignee .. 142
Table 69 Number of Patent Applications, Ebola, by Year, 2010-2016 .. 145
Table 70 Number of Patent Applications, Ebola, by Country 146
Table 71 Number of Patent Applications, Ebola, by Type .. 147
Table 72 Number of Patent Applications, Zika, by Assignee . 148
Table 73 Number of Patent Applications, Zika, by Year, 2010-2016 . 149
Table 74 Number of Patent Applications, Zika, by Country . 150
Table 75 Number of Patent Applications, Zika, by Type .. 151
Table 76 Abbreviations Used in Neglected Tropical Diseases Landscape .. 174
Table 77 Glossary of Terms Used in Neglected Tropical Diseases Landscape .. 176
Table 78 Report Sources .. 177

List of Figures
Summary Figure: Global Market for Neglected Tropical Diseases, by Indication, 2015-2021 ($ Millions)
.. 15
Figure 1 Global Number of Malaria Caused Deaths, 2011-2015 21
Figure 2 Global Number of Leishmaniasis Caused Deaths, 2011-2015 .. 27
Figure 3 Global Leishmaniasis Years of Life Lost*, 2011-2015 . 28
Figure 4 Global Number of Schistosomiasis Caused Deaths, 2011-2015 .. 31
Figure 5 Global Schistosomiasis Years of Life Lost*, 2011-2015 . 32
Figure 6 Number of Lymphatic Filariasis Endemic Countries, by Region 33
Figure 7 Number of Chagas Disease Caused Deaths, 2011-2015 .. 37
Figure 8 Global Chagas Disease Years of Life Lost*, 2011-2015 . 38
Figure 9 Number of Cases of African Trypanosomiasis, T.b. gambiense, 2011-2015 .. 39
Figure 10 Number of Cases of African Trypanosomiasis, T.b. rhodesiense, 2011-2015 . 40
Figure 11 Global Number of African Trypanosomiasis Caused Deaths, 2011-2015 . 41
Figure 12 Global African Trypanosomiasis Years of Life Lost*, 2011-2015 .. 42
Figure 13 Average Annual Number of Dengue Fever Cases, 1960-2007 44
Figure 14 Number of Cases in American Region, 2012-2016 .. 44
Figure 15 Incidence Rate (per 100,000 Inhabitants) in American Region, 2012-2016 45
Figure 16 Global Number of Dengue Caused Deaths, 2011-2015 . 46
Figure 17 Global Dengue Caused Years of Life Lost*, 2011-2015 .. 46
Figure 18 Outbreaks in West Africa Affected Countries (Guinea, Liberia, Sierra Leone), by Total Number
of Cases, March 2014-February 2016 .. 48
Figure 19 Outbreaks in West Africa Affected Countries (Guinea, Liberia, Sierra Leone), by Total Number
of Deaths, March 2014-February 2016 . 49
Figure 20 Number of Countries (Y) with Number of Confirmed Zika Cases (X), by American Region, 2015-
2016 50
Figure 21 Global Addressable Market for Neglected Tropical Diseases, by Indication, 2015-2021 ($
Millions) 55
Figure 22 Global Market for Malaria, by Region, 2014-2021 ($ Millions). 57
Figure 23 Global Market for Leishmaniasis, by Region, 2014-2021 ($ Millions) 59
Figure 24 Global Market for Schistosomiasis, by Region, 2014-2021 ($ Millions) 61
Figure 25 Global Market for Lymphatic Filariasis, by Region, 2014-2021 ($ Millions) .. 62
Figure 26 Global Market for Chagas Disease, by Geography, 2014-2021 ($ Millions) .. 64
Figure 27 Global Market for Dengue, by Region, 2014-2021 ($ Millions) 66
Figure 28 Global Market for Zika, by Region, 2014-2021 ($ Millions) 69
Figure 29 Clinical Trials in Malaria, by Intervention Type, January 2005-September 2016 (%) .. 90
Figure 30 Top 20 Sponsors/Collaborators, by Clinical Trials in Malaria, January 2005-September 2016 91
Figure 31 Clinical Trials in Leishmaniasis, by Intervention Type, January 2005-September 2016 (%) .. 93
Figure 32 Key Sponsors/Collaborators, Clinical Trials in Leishmaniasis, January 2005-September 2016 94
Figure 33 Clinical Trials in Schistosomiasis, by Intervention Type, January 2005-September 2016 (%) 95
Figure 34 Key Sponsors/Collaborators, Clinical Trials in Lymphatic Filariasis, January 2005-September
2016 97
Figure 35 Clinical Trials in Chagas Disease, by Intervention Type, January 2005-September 2016 (%) 99
Figure 36 Key Sponsors/Collaborators, Clinical Trials in Chagas Disease, January 2005-September 2016
100
Figure 37 Clinical Trials in Dengue, by Intervention Type, January 2005-September 2016 (%) .. 103
Figure 38 Key Sponsors/Collaborators, Clinical Trials in Dengue, January 2005-September 2016 .. 104
Figure 39 Clinical Trials in Ebola, by Intervention Type, January 2005-September 2016 (%) .. 106
Figure 40 Key Sponsors/Collaborators, Clinical Trials in Ebola, January 2005-September 2016 107
Figure 41 Key Sponsors/Collaborators, Clinical Trials in Zika, January 2005-September 2016 .. 110
Figure 42 Patent Share for Treatment and Preventive Medicine in Malaria, by Year (%) . 115
Figure 43 Patent Share for Treatment and Preventive Medicine in Malaria, US and non-US (%) . 117
Figure 44 Patent Share for Treatment and Preventive Medicine in Leishmaniasis, by Year (%) 120
Figure 45 Patent Share for Leishmaniasis, US and non-US (%) . 122
Figure 46 Patent Share for Treatment and Preventive Medicine in Schistosomiasis, by Year (%) . 124
Figure 47 Patent Share for Schistosomiasis, U.S. and non-U.S. (%) 125
Figure 48 Patent Share for Treatment and Preventive Medicine in Lymphatic Filariasis, by Year (%) 127
Figure 49 Patent Share for Lymphatic Filariasis, U.S. and non-U.S. (%) 128
Figure 50 Patent Share for Treatment and Preventive Medicine in Chagas Disease, by Year (%) 131
Figure 51 Patent Share for Chagas Disease, by U.S. and non-U.S. (%) . 132
Figure 52 Patent Share for Treatment and Preventive Medicine in African Trypanosomiasis, by Year (%)
134
Figure 53 Patent Share for African Trypanosomiasis, US and non-US (%) . 135
Figure 54 Patent Share for Treatment and Preventive Medicine in Dengue, by Year (%) . 139
Figure 55 Patent Share for Dengue, U.S. and non-U.S. (%). 141
Figure 56 Patent Share for Treatment and Preventive Medicine in Ebola, by Year (%) .. 145
Figure 57 Patent Share for Ebola, U.S. and non-U.S. (%) 147
Figure 58 Patent Share for Treatment and Preventive Medicine in Zika, by Year (%) . 149
Figure 59 Patent Share for Zika, U.S. and Non-U.S. (%) .. 150
Figure 60 DNDi - Research Portfolio, by Phase of Development (%) .. 156
Figure 61 DNDi - Research Portfolio, by Indication (%) .. 157
Figure 62 GlaxoSmithKline - Research Portfolio, by Phase of Development (%) 161
Figure 63 GlaxoSmithKline - Research Portfolio, by Indication (%) .. 162
Figure 64 MMV - Research Portfolio, by Phase of Development 165
Figure 65 MMV - Research Portfolio, by Partner (%) 166